gerald s. werner, md, fesc, facc klinikum darmstadt, germany
DESCRIPTION
BSIC, Manchester, September 15, 2006. Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany. BSIC, Manchester, September 15, 2006. Chronic total occlusions update A European perspective. Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany. CTO – The European perspective. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/1.jpg)
Gerald S. Werner, MD, FESC, FACC
Klinikum Darmstadt, Germany
BSIC, Manchester, September 15, 2006
![Page 2: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/2.jpg)
Chronic total occlusions updateChronic total occlusions update
A European perspectiveA European perspective
Chronic total occlusions updateChronic total occlusions update
A European perspectiveA European perspective
Gerald S. Werner, MD, FESC, FACC
Klinikum Darmstadt, Germany
BSIC, Manchester, September 15, 2006
![Page 3: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/3.jpg)
CTO – The European perspectiveCTO – The European perspectiveCTO – The European perspectiveCTO – The European perspective
• What you may want to know about collaterals
• Why should we open a CTO ?
• The past and presence of CTO treatment
• CTOs in the DES era
• The remaining challenges in CTOs
![Page 4: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/4.jpg)
Pathophysiology of collaterals in CTOsPathophysiology of collaterals in CTOsPathophysiology of collaterals in CTOsPathophysiology of collaterals in CTOs
• How to assess collaterals ?
• What happens to collaterals after PCI ?
• Can collaterals replace an open artery ?
![Page 5: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/5.jpg)
Assessment of collaterals: pressure Assessment of collaterals: pressure andand flow flowAssessment of collaterals: pressure Assessment of collaterals: pressure andand flow flow
P A o
P O ccl APV O ccl
R C o ll
R P
P A o
P O ccl APV O ccl
R C o llP ressure/D oppler W ire
P ressure/D oppler W ire
Before recanalization R eocclusion after PTC A
TC O Balloon
RA RA
R P
Baseline collateral function
P A o
P O ccl APV O ccl
R C o ll
R P
P A o
P O ccl APV O ccl
R C o llP ressure/D oppler W ire
P ressure/D oppler W ire
Before recanalization R eocclusion after PTC A
TC O Balloon
RA RA
R P
Recruitable collateral function
Werner et al. Circulation 2001;104:2784-90
![Page 6: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/6.jpg)
Collateral function in CTOsCollateral function in CTOsCollateral function in CTOsCollateral function in CTOs
0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,70
5
10
15
20N
um
ber
of patie
nts
Collateral pressure index
0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,70
5
10
15
20
Num
ber
of patie
nts
Collateral pressure index
79%79% 46%46%
Werner et al. Circulation 2003;108:2877-82
Before PCI After PCI
![Page 7: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/7.jpg)
Loss of collateral function not due to Loss of collateral function not due to embolizationembolization
Loss of collateral function not due to Loss of collateral function not due to embolizationembolization
0 25 50 75
Rcoll [mmHg/(cm*sec)]
0,0
0,5
1,0
1,5
2,0
max
imal
e C
K [
µm
ol/(
L*s
ec)]
R-Quadrat = 0,01
Bahrmann et al. Z Kardiol 2002;91:937-945
![Page 8: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/8.jpg)
Collateral function in CTOsCollateral function in CTOsCollateral function in CTOsCollateral function in CTOs
0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,70
5
10
15
20N
um
ber
of patie
nts
Collateral pressure index
0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,70
5
10
15
20
Num
ber
of patie
nts
Collateral pressure index
79%79% 46%46%
0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,70
5
10
15
20
Num
ber
of patie
nts
Collateral pressure index
18%18%
Werner et al. Circulation 2003;108:2877-82
Before PCI After PCI
6 mo FUP
![Page 9: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/9.jpg)
Evidence for preformed collaterals in manEvidence for preformed collaterals in manEvidence for preformed collaterals in manEvidence for preformed collaterals in man
0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,70
5
10
15
20N
um
ber
of patie
nts
Collateral pressure index
0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,70
5
10
15
20
Num
ber
of patie
nts
Collateral pressure index
79%79% 46%46%
0,0 0,1 0,2 0,3 0,4 0,5 0,6 0,70
5
10
15
20
Num
ber
of patie
nts
Collateral pressure index
18%18%
20%20%
Wustmann et al. Circulation 2003;107:2213-20 Werner et al. Circulation 2003;108:2877-82
Before PCI After PCI
6 mo FUP
![Page 10: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/10.jpg)
Can good collaterals replace an open artery Can good collaterals replace an open artery ??
Can good collaterals replace an open artery Can good collaterals replace an open artery ??
Collateral function assessed as collateral flow reserveIn 98 Pat. with CTO during adenosine stress
Adapted from Werner et al. JACC 2006;48:51-8
![Page 11: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/11.jpg)
Can good collaterals replace an open artery Can good collaterals replace an open artery ??
Can good collaterals replace an open artery Can good collaterals replace an open artery ??
95% of collaterals are no substitute for the open artery
![Page 12: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/12.jpg)
CTO – The European perspectiveCTO – The European perspectiveCTO – The European perspectiveCTO – The European perspective
• What you may want to know about collaterals
• Why should we open a CTO ?
• The past and presence of CTO treatment
• CTOs in the DES era
• The remaining challenges in CTOs
![Page 13: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/13.jpg)
CTOs – Should we treat them all ?CTOs – Should we treat them all ?CTOs – Should we treat them all ?CTOs – Should we treat them all ?
• Improvement of symptoms (angina, dyspnea)
• Improvement of LV function
• Improvement of prognosis
![Page 14: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/14.jpg)
Benefit of recanalisation on LV functionBenefit of recanalisation on LV functionBenefit of recanalisation on LV functionBenefit of recanalisation on LV function
Werner et al. Am Heart J 2005;149:129-37
No improvement in case ofReocclusion !!!
![Page 15: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/15.jpg)
Indication for revascularization: MRI Indication for revascularization: MRI function and vitalityfunction and vitality
Indication for revascularization: MRI Indication for revascularization: MRI function and vitalityfunction and vitality
![Page 16: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/16.jpg)
LV recovery after recanalization of CTOs - LV recovery after recanalization of CTOs - MRIMRI
LV recovery after recanalization of CTOs - LV recovery after recanalization of CTOs - MRIMRI
Baks T et al. JACC 2006;47:721-5
![Page 17: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/17.jpg)
PCI success and PCI success and survivalsurvival
PCI success and PCI success and survivalsurvival
Suero et al. JACC 2001;38:409-14
Ramanathan & Buller, ACC 2003
2000 Pat, 74% successful
1458 Pat, 77% successful
871 Pat, 65% successfulHoye et al. Eur Heart J 2005;26:2630-6
![Page 18: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/18.jpg)
If PCI fails … at least consider CABGIf PCI fails … at least consider CABGIf PCI fails … at least consider CABGIf PCI fails … at least consider CABG
Suero et al. JACC 2001;38:409-14
But CABG seems to be only the second best option
![Page 19: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/19.jpg)
A CTO left occluded makes life more A CTO left occluded makes life more dangerousdangerous
A CTO left occluded makes life more A CTO left occluded makes life more dangerousdangerous
![Page 20: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/20.jpg)
Leaving a CTO alone means taking risks in low Leaving a CTO alone means taking risks in low risk patientsrisk patients
Leaving a CTO alone means taking risks in low Leaving a CTO alone means taking risks in low risk patientsrisk patients
0
1
2
3
4
5
6
7
8
PeriproceduralMACE
Death within 12months
CTO (n=122)Non-CTO (n=88)No PCI (n=451)
STAR Registry, Institute for infarct research, Ludwigshafen
PCI of
![Page 21: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/21.jpg)
CTO – The European perspectiveCTO – The European perspectiveCTO – The European perspectiveCTO – The European perspective
• What you may want to know about collaterals
• Why should we open a CTO ?
• The past and presence of CTO treatment
• CTOs in the DES era
• The remaining challenges in CTOs
![Page 22: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/22.jpg)
CTOs in the cathlab routine in 2003CTOs in the cathlab routine in 2003CTOs in the cathlab routine in 2003CTOs in the cathlab routine in 2003
• In a German registry (STAR – Stable Angina pectoris Registry - IHF, Ludwigshafen) 2002 consecutive diagnostic angiographies were evaluated:• 33% had at least one CTO• CTO pts had more severe symptoms, and LV
dysfunction• the 1-year mortality with CTOs was 5.5% vs. 3.1%
• Only one third of CTOs underwent PCI• Half of all CTOs were referred to CABG
![Page 23: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/23.jpg)
Why bother, you can‘t open it … most timesWhy bother, you can‘t open it … most timesCTO success rates – historical perspectiveCTO success rates – historical perspective
Why bother, you can‘t open it … most timesWhy bother, you can‘t open it … most timesCTO success rates – historical perspectiveCTO success rates – historical perspective
![Page 24: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/24.jpg)
Why bother with PCI – you can‘t keep it Why bother with PCI – you can‘t keep it open anyhowopen anyhow
Binary angiographic restenosis with balloon vs BMSBinary angiographic restenosis with balloon vs BMS
Why bother with PCI – you can‘t keep it Why bother with PCI – you can‘t keep it open anyhowopen anyhow
Binary angiographic restenosis with balloon vs BMSBinary angiographic restenosis with balloon vs BMS
Woehrle CTO Workshop Munich 2005
![Page 25: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/25.jpg)
Stenting in CTOs: long and multiple stents Stenting in CTOs: long and multiple stents requiredrequired
Stenting in CTOs: long and multiple stents Stenting in CTOs: long and multiple stents requiredrequired
Werner et al. J Am Coll Cardiol 2003;42:219-25
1 2 >20
10
20
30
40
50
60
70
80
90
100
4
11
9
17
5
10
61628
Pa
tient
s [%
]
Number of implanted stents
No TVF Restenosis Reocclusion
1 2 >20
10
20
30
40
50
60
70
80
90
100
4
11
9
17
5
10
61628
Pa
tient
s [%
]
Number of implanted stents
No TVF Restenosis Reocclusion
1 2 >20
10
20
30
40
50
60
70
80
90
100
4
11
9
17
5
10
61628
Pa
tient
s [%
]
Number of implanted stents
No TVF Restenosis Reocclusion
1 2 >20
10
20
30
40
50
60
70
80
90
100
4
11
9
17
5
10
61628
Pa
tient
s [%
]
Number of implanted stents
No TVF Restenosis Reocclusion
![Page 26: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/26.jpg)
CTO – The European perspectiveCTO – The European perspectiveCTO – The European perspectiveCTO – The European perspective
• What you may want to know about collaterals
• Why should we open a CTO ?
• The past and presence of CTO treatment
• CTOs in the DES era
• The remaining challenges in CTOs
![Page 27: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/27.jpg)
Published studies using DES in CTOsPublished studies using DES in CTOsPublished studies using DES in CTOsPublished studies using DES in CTOs
Hoye Ge Nakamura Prison II PACTO
Stent Cypher Cypher Cypher Cypher Taxus
Patients 56 122 60 100 95
Reference diameter [mm] 2.35 2.67 3.12 3.38 2.65
Stent length 24 42 36.5 32 40
Stents per lesion 2.0 1.4 1.4 ? 1.4 1.7
TVF 9 % 9 % 3 % 8 % 10 %
Reocclusion 3 % 2.5 % 0 % 4 % 1 %
Follow-up 59 % 83 % 75 % 94 % 100 %
![Page 28: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/28.jpg)
Events in PRISON II: BMS vs. CypherEvents in PRISON II: BMS vs. CypherEvents in PRISON II: BMS vs. CypherEvents in PRISON II: BMS vs. Cypher
Suttorp et al. TCT 2005
![Page 29: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/29.jpg)
30 90 1500 60 120 210180 240 270
Days Since Index Procedure
300 330 360
100%
90%
80%
70%
Fre
edom
of
TLR
TAXUS MRControl
9 mos. 12 mos.
P=0.0003
91.3 %
79.4 %
Control=bare metal stent
TAXUS= TAXUSTM stent
TAXUSTM MR stent is not available for sale
CTO vs. Complex Nonocclusive Lesions CTO vs. Complex Nonocclusive Lesions (Taxus VI)(Taxus VI)
CTO vs. Complex Nonocclusive Lesions CTO vs. Complex Nonocclusive Lesions (Taxus VI)(Taxus VI)
12%NNT 8
Werner et al. J Am Coll Cardiol 2004;44:2301-6
35%NNT 3
![Page 30: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/30.jpg)
Long stenting no longer a problem for Long stenting no longer a problem for recurrencerecurrence
Long stenting no longer a problem for Long stenting no longer a problem for recurrencerecurrence
2.75x32
3.0x32
3.0x28
3.0x323.5x8
2214/05 471/05
6 months later
![Page 31: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/31.jpg)
Taxus restenosis in CTOs: focalTaxus restenosis in CTOs: focalTaxus restenosis in CTOs: focalTaxus restenosis in CTOs: focal
All nonocclusive restenosis were focal at the edges andsuccessfully treated with another Taxus stent ->99 % patency
![Page 32: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/32.jpg)
95 pts
85 pts.No TVF
10 pts.TVF
93 pts.
9 pts.Repeat PCI
6 months
1 pt. Reoccl.No PCI
9 pts. *)No TVF12 months
1 pt. LateReoccl.
Longterm patencyLongterm patencyLongterm patencyLongterm patency
Werner GS et al; ACC 2006
![Page 33: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/33.jpg)
0
2
4
6
8
10
12
Overall Cardiac Death
TLRMI
1.7% n=1
1.7%n=1
6.7%n=4
Inci
den
ce
(%
)
N = 65/778 Patients
WISDOM 12-Month TAXUS Related WISDOM 12-Month TAXUS Related Cardiac Events: Total OcclusionsCardiac Events: Total Occlusions
WISDOM 12-Month TAXUS Related WISDOM 12-Month TAXUS Related Cardiac Events: Total OcclusionsCardiac Events: Total Occlusions
3.3% n=2
Only 8.4% !!!
![Page 34: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/34.jpg)
0
2
4
6
8
10
Overall Cardiac Death
Treated Vessel Re-intervention
MI
2.2% n=41.1%
n=2
4.3%n=8
Inci
den
ce
(%
)
N = 186/3688 Patients
MILESTONE II 12-Month TAXUS Related MILESTONE II 12-Month TAXUS Related Cardiac Events: Total OcclusionsCardiac Events: Total Occlusions
MILESTONE II 12-Month TAXUS Related MILESTONE II 12-Month TAXUS Related Cardiac Events: Total OcclusionsCardiac Events: Total Occlusions
1.6% n=3
Stent thrombosis = 1.0% (2/186)
Only 5% !!!
![Page 35: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/35.jpg)
Opening a CTO …Opening a CTO …Opening a CTO …Opening a CTO …
• Improves symptoms (angina, dyspnea)
• Improves LV function
• Improves prognosis
• Can be kept open with DES
• Why are they still undertreated ?
![Page 36: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/36.jpg)
CTO success ratesCTO success ratesCTO success ratesCTO success rates
1995/96 1997/98 1999/01 2001/03
![Page 37: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/37.jpg)
Penetration power of dedicated wiresPenetration power of dedicated wiresPenetration power of dedicated wiresPenetration power of dedicated wires
![Page 38: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/38.jpg)
New wire techniquesNew wire techniquesNew wire techniquesNew wire techniques
Mitsudo; www.tctmd.com
![Page 39: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/39.jpg)
Parallel wire technique - exampleParallel wire technique - exampleParallel wire technique - exampleParallel wire technique - example
230/05
Parallel wire technique with ASAHIMiracle Bros and Conquest wires
![Page 40: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/40.jpg)
Case example: Double blunt occlusionCase example: Double blunt occlusionCase example: Double blunt occlusionCase example: Double blunt occlusion
12/05/06
Blunt proximal cap with 2 large sidebranches and blunt distal cap with one large side branch.
![Page 41: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/41.jpg)
Case example: Double blunt occlusionCase example: Double blunt occlusionCase example: Double blunt occlusionCase example: Double blunt occlusion
12/05/06
Bilateral approach: Confianza Pro over Spectranetics versus Miracle 3G over Transit
![Page 42: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/42.jpg)
Case example: Double blunt occlusionCase example: Double blunt occlusionCase example: Double blunt occlusionCase example: Double blunt occlusion
12/05/06
Bilateral approach: A major new option for 2nd attempts But the majority of CTOs are not treated in live courses
![Page 43: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/43.jpg)
Determinants of procedural successDeterminants of procedural successDeterminants of procedural successDeterminants of procedural success
• Experience, dedication and patience of interventionist
• Duration of occlusion• < > 2 weeks• < > 3 months• < > 12 months
• Angiographic criteria … not many• Heavy calcification• Vessel tortuosity
![Page 44: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/44.jpg)
PCI of CTOs is dangerous … really ?PCI of CTOs is dangerous … really ?PCI of CTOs is dangerous … really ?PCI of CTOs is dangerous … really ?
Bahrmann et al. EuroInterv 2006;2:231-7
![Page 45: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/45.jpg)
Why do we not apply what is possible ?Why do we not apply what is possible ?Why do we not apply what is possible ?Why do we not apply what is possible ?
1995/961997/981999/012006
![Page 46: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/46.jpg)
CTO – The European realityCTO – The European realityCTO – The European realityCTO – The European reality
• Opening a CTO …
• Costs a lot of lab time• Costs a lot of work time• Costs a lot of material• Costs a lot of radiation exposure• Requires a lot of patience
• Does not pay in our reimbursement system
![Page 47: Gerald S. Werner, MD, FESC, FACC Klinikum Darmstadt, Germany](https://reader034.vdocument.in/reader034/viewer/2022052217/5681479f550346895db4d7ff/html5/thumbnails/47.jpg)